Vaccinia virus recombinants encoding the truncated structural gene region of Venezuelan equine encephalitis virus (VEEV) give solid protection against peripheral challenge but only partial protection against airborne challenge with virulent VEEV

Acta Virologica

Volumn 44, Issue 5, 2000, Pages 233-239

  Phillpotts, R J ^a   Lescott, T L ^a   Jacobs, S C ^a  

^a DERA   (United Kingdom)

Author keywords

Protective immunity; Vaccinia virus; Venezuelan equine encephalitis virus

Indexed keywords

ANTIBODY; IMMUNOGLOBULIN A;

ANIMAL CELL; ANIMAL EXPERIMENT; ANTIBODY RESPONSE; ANTIGEN EXPRESSION; ARTICLE; CONTROLLED STUDY; GENE EXPRESSION; IMMUNE RESPONSE; IMMUNITY; IMMUNOGENICITY; MOLECULAR CLONING; MOUSE; NONHUMAN; PROVOCATION TEST; STRUCTURAL GENE; VACCINIA VIRUS; VENEZUELAN EQUINE ENCEPHALOMYELITIS ALPHAVIRUS; VIRUS RECOMBINANT; VIRUS VIRULENCE;

ANIMALS; ANTIBODIES, VIRAL; CELL LINE; ENCEPHALITIS VIRUS, VENEZUELAN EQUINE; ENCEPHALOMYELITIS, VENEZUELAN EQUINE; GENETIC VECTORS; HORSES; IMMUNITY, MUCOSAL; IMMUNOGLOBULIN G; MICE; MICE, INBRED BALB C; VACCINATION; VACCINES, SYNTHETIC; VACCINIA VIRUS; VIRAL STRUCTURAL PROTEINS; VIRAL VACCINES; VIRULENCE;

EID: 0033668530     PISSN: 0001723X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (36)

1. Live, attenuated Venezuelan equine encephalomyelitis vaccine
2. Improved protection against Venezuelan equine encephalitis by genetic engineering of a recombinant vaccinia virus
3. Attenuation of Venezuelan equine encephalomyelitis virus by in vitro cultivation in guinea pig heart cells
4. 3,3',5,5',-tetramethylbenzidine as an Ames test negative chromogen for horseradish peroxidase in enzyme-immunoassay
5. Decreased virulence of recombinant vaccinia virus expression vectors is associated with a thymidine kinase-negative phenotype
6. TC83 Venezuelan encephalitis exposure during pregnancy
7. Inactivated with Venezuelan equine encephalomyelitis vaccine prepared from attenuated (TC-83 strain) virus
8. IgG2a restriction of murine antibodies elicited by viral infections
9. Escherichia coli gpt gene provides dominant selection for vaccinia virus open reading frame vectors
10. Effecto teratogenico del virus de la encefalitis equina Venezolana, una revision del problema
11. Induction of protective immune responses against Venezuelan equine encephalitis (VEE) virus aerosol challenge with microencapsulated VEE virus vaccine
12. Method for quantitation of IgG subclass antibodies in mouse serum by enzyme-linked immunosorbent assay
13. Venezuelan equine encephalitis virus vaccines induce mucosal IgA responses and protection from airborne infection in Balb/c but not C3H/HeN mice
14. Expression, processing and immunogenicity of the structural proteins of Venezuelan equine encephalitis virus from recombinant baculovirus vectors
15. Protective efficacies of live-attenuated and formaldehyde-inactivated Venezuelan equine encephalitis virus vaccines against aerosol challenge in hamsters
16. Venezuelan equine encephalitis
17. Recombinant vaccinia/Venezuelan equine encephalitis (VEE) virus protects mice from peripheral VE virus challenge
18. The full-length sequences of the virulent Trinidad donkey strain of Venezuelan equine encephalitis virus and its attenuated vaccine derivative, strain TC-83
19. Alphavirus-specific cytotoxic T lymphocytes recognise a cross-reactive epitope from the capsid protein and can eliminate virus from persistenly infected macrophages
20. The construction and characterisation of vaccinia virus recombinants expressing foreign genes
21. A 15 year review (1976-1990) of the safety and immunigenicity of VEE live, attenuated TC-83 and formalin-inactivated, C-84 vaccines
22. Determination of the protective epitopes on the glycoproteins of Venezuelan equine encephalomyelitis virus by passive transfer of monoclonal antibodies
23. Role of complement and the Fc portion of immunoglobulin G in immunity Venezuelan equine encephalomyelitis virus infection with glycoprotein-specific monoclonal antibodies
24. Genetically engineered poxviruses for recombinant gene expression, vaccination and safety
25. Glycoproteins E2 of the Venezuelan and Eastern equine encephalomyelitis viruses contain multiple cross-reactive epitopes
26. TC-83 vaccine protects against disease produced by airborne or subcutaneous infection with heterologous mouse-virulent strains of Venezuelan equine encephalitis virus
27. Immunity to airborne challenge with Venezuelan equine encephalitis virus develops rapidly after immunisation with the attenuated vaccine strain TC-83
28. A simple device for exposure of animals to infectious micro-organisms by the airborne route
29. Long-term duration of detectable neutralizing antibodies after administration of live-attenuated VEE vaccine and following booster vaccination with inactivated VEE vaccine
30. Epidemic Venezuelan encephalitis in La Guajira, Colombia, 1995
31. In vitro mechanisms of monoclonal antibody neutralisation of alphaviruses
32. The alphaviruses: Gene expression, replication and evolution
33. Immunogenic properties of a recombinant vaccinia virus with incorporated cDNA copy of 26S RNA of Venezuelan equine encephalomyelitis virus
34. Laboratory safety for arboviruses and certain other viruses of vertebrates
35. Humane endpoints are an objective measure of morbidity in Venezuelan encephalomyelitis virus infection of mice